Evidence map›Paper›PMID 28831439›Full record

ArticleJournal of global oncology2017

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.

Ettienne J Myburgh, Lizanne Langenhoven, Kathleen A Grant, Lize van der Merwe, Maritha J Kotze

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ettienne J MyburghUniversity of Stellenbosch, Tygerberg; , Mediclinic Panorama Hospital, Cape Town; , Cape Peninsula University of Technology; , University of Western Cape, Bellville; and , University of Stellenbosch and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
Lizanne LangenhovenUniversity of Stellenbosch, Tygerberg; , Mediclinic Panorama Hospital, Cape Town; , Cape Peninsula University of Technology; , University of Western Cape, Bellville; and , University of Stellenbosch and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
Kathleen A GrantUniversity of Stellenbosch, Tygerberg; , Mediclinic Panorama Hospital, Cape Town; , Cape Peninsula University of Technology; , University of Western Cape, Bellville; and , University of Stellenbosch and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
Lize van der MerweUniversity of Stellenbosch, Tygerberg; , Mediclinic Panorama Hospital, Cape Town; , Cape Peninsula University of Technology; , University of Western Cape, Bellville; and , University of Stellenbosch and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
Maritha J KotzeUniversity of Stellenbosch, Tygerberg; , Mediclinic Panorama Hospital, Cape Town; , Cape Peninsula University of Technology; , University of Western Cape, Bellville; and , University of Stellenbosch and National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHuman epidermal growth factor receptor 2 (HER2) positivity is an important prognostic and predictive indicator in breast cancer. HER2 status is determined by immunohistochemistry and fluorescent in situ hybridization (FISH), which are potentially inaccurate techniques as a result of several technical factors, polysomy of chromosome 17, and amplification or overexpression of CEP17 (centromeric probe for chromosome 17) and/or HER2. In South Africa, HER2-positive tumors are excluded from a MammaPrint (MP; Agendia BV, Amsterdam, Netherlands) pretest algorithm. Clinical HER2 status has been reported to correlate poorly with molecular subtype. The aim of this study was to investigate the correlation of clinical HER2 status with BluePrint (BP) molecular subtyping.

methodsClinico-pathologic and genomic information was extracted from a prospectively collected central MP database containing records of 256 estrogen receptor-positive and/or progesterone receptor-positive tumors. Twenty-one tumors considered HER2 positive on immunohistochemistry or FISH were identified for this study.

resultsThe median age of patients was 56 years (range, 34 to 77 years), with a median tumor size of 16 mm (3 to 27 mm). Four (19%) tumors were confirmed HER2-enriched subtype, six (29%) were luminal A, and 11 (52%) were luminal B. The positive predictive values of HER2/CEP17 ratio ≥ 2 and HER2 copy number ≥ 6 were only 29% and 40%, respectively. The differences in means for HER2/CEP17 ratio were significant between BP HER2-enriched versus luminal (

conclusionOf the 21 tumors considered clinically HER2 positive, only four were HER2-enriched subtype with BP, indicating an overestimation of HER2 positivity. FISH testing has a poor positive predictive value.

Identifiers

PMID28831439
PMCPMC5560457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.